Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis
✍ Scribed by Vlastimir Mladenovic; Zlatko Domljan; Blaz Rozman; Ivo Jajic; Dimitrije Mihajlovic; Jovan Dordevic; Milan Popovic; Miroslava Dimitrijevic; Milutin Zivkovic; Giles Campion; Predrag Musikic; Iris Löw-Friedrich; Christine Oed; Hildegard Seifert; Vibeke Strand
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 844 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Objective: To determine whether treatment with leflunomide (lef), methotrexate (mtx), or sulfasalazine (ssz) for 6-12 months retards progression of radiographic damage and to identify clinical variables that correlate with radiographic progression. ## Methods: Radiographs of the hands and feet
## Abstract ## Objective To investigate the efficacy and safety of leflunomide beyond 2 years in a multinational, open‐label extension of 2 phase III double‐blind studies. ## Methods Patients with rheumatoid arthritis (RA) who received leflunomide (100 mg/day for 3 days, 10 mg/day or 20 mg/day t
## Objective: To report the safety and efficacy of leflunomide (lef) in combination with infliximab (inf) for the treatment of rheumatoid arthritis. ## Methods: In an open, multicenter, retrospective study, data were collected on the safety and efficacy of lef and inf. ## Results: Eighty-eight